LncRNA-DGCR5在非小细胞肺癌中的表达及与放疗疗效、预后的相关性分析

韩康; 景文江; 伍永升; 李源; 范志刚

doi:10.16766/j.cnki.issn.1674-4152.003867

LncRNA-DGCR5在非小细胞肺癌中的表达及与放疗疗效、预后的相关性分析

doi: 10.16766/j.cnki.issn.1674-4152.003867

1.
三二〇一医院呼吸与危重症医学科, 陕西汉中 723000
2.
三二〇一医院放疗科
3.
三二〇一医院肿瘤内一科

基金项目:

陕西省重点研发计划项目 2021SF-044

详细信息

通讯作者:
景文江, E-mail: 57008049@ qq. com

中图分类号: R734.2 R730.55
计量
- 文章访问数: 11
- HTML全文浏览量: 4
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-07-21
- 网络出版日期: 2025-03-27

Expression of LncRNA-DGCR5 in non-small cell lung cancer and its correlation with radiotherapy efficacy and prognosis

1.
Department of Respiratory and Critical Care Medicine, 3201 Hospital, Hanzhong, Shaanxi 723000, China

摘要

摘要: 目的探讨LncRNA-DGCR5在非小细胞肺癌(NSCLC)中的表达及临床意义。方法收集2020年1月— 2021年1月三二〇一医院收治的105例NSCLC患者, 根据LncRNA-DGCR5表达情况分为低表达组(41例)和高表达组(64例), 分析LncRNA-DGCR5表达量与患者放疗疗效、预后的关系。结果癌组织LncRNA-DGCR5表达水平低于癌旁组织(1. 21±0. 45 vs. 4. 02±0. 89, t = 28. 872, P < 0. 05)。低表达组相比于与高表达组肿瘤低分化占比、TNM分期为Ⅲ~ Ⅳ期占比更高(63. 41% vs. 17. 19%, χ² = 23. 401, P < 0. 05;56. 10% vs. 32. 81%, χ² = 5. 566, P < 0. 05), 客观缓解率更低(46. 34% vs. 87. 50%, χ² = 27. 648, P < 0. 05), 3年无病生存时间(DFS)更短(27. 00个月vs. 31. 00个月, log-rank χ² = 10. 120, P < 0. 05)。肿瘤低分化、TNM分期为Ⅲ ~ Ⅳ期、存在淋巴结转移患者中位DFS更低, 分别为28. 15、28. 66、27. 45个月(χ² = 9. 074、5. 105、12. 116, 均P < 0. 05)。肿瘤分化程度、TNM分期、淋巴结转移及LncRNA-DGCR5表达均为影响NSCLC患者中位DFS的相关因素(P < 0. 05)。结论 LncRNA-DGCR5在NSCLC癌组织中呈低表达, 与患者放疗疗效及预后密切相关。
- LncRNA-DGCR5 /
- 非小细胞肺癌 /
- 放疗疗效 /
- 预后
Abstract: Objective To investigate the expression and clinical significance of LncRNA-DGCR5 in non-small cell lung cancer (NSCLC). Methods A total of 105 NSCLC patients admitted to 3201 Hospital from January 2020 to January 2021 were collected. The expression levels of LncRNA-DGCR5 were detected, and the patients were divided into a low expression group (n = 41) and a high expression group (n = 64). The relationship between the expression level of LncRNADGCR5, the radiotherapy efficacy, and prognosis of patients was analyzed. Results The expression level of LncRNADGCR5 in cancer tissues was significantly lower than that in adjacent tissues (1. 21±0. 45 vs. 4. 02±0. 89, t = 28. 872, P < 0. 05). Compared with the high expression group, the proportion of poorly differentiated tumor and TNM stage Ⅲ to Ⅳ in the low expression group was higher (63. 41% vs. 17. 19%, 56. 10% vs. 32. 81%, χ² = 23. 401, 5. 566, P < 0. 05). In contrast to the high expression group, the objective response rate was lower (46. 34% vs. 87. 50%, χ² = 27. 648, P < 0. 05), and the 3-year disease-free survival (DFS) was shorter (27. 00 months vs. 31. 00 months, log-rank χ² = 10. 120, P < 0. 05) in the low expression group. Additionally, patients with low tumor differentiation, TNM stage Ⅲ to Ⅳ, and lymph node metastasis had lower median DFS (28. 15, 28. 66, 27. 45 months, respectively, χ² = 9. 074, 5. 105, 12. 116, all P < 0. 05). Tumor differentiation, TNM stage, lymph node metastasis, and LncRNA-DGCR5 expression were all significantly associated with median DFS in NSCLC patients (P < 0. 05). Conclusion LncRNA-DGCR5 is expressed at low levels in NSCLC tissues and is closely related to the radiotherapy efficacy and patient prognosis.
- LncRNA-DGCR5 /
- Non-small cell lung cancer /
- Radiotherapy efficacy /
- Prognosis

HTML全文

图 1 不同LncRNA-DGCR5表达状态患者随访期间DFS生存曲线

Figure 1. DFS survival curve of patients with different LncRNA-DGCR5 expression status during follow-up

下载: 全尺寸图片幻灯片

表 1 不同LncRNA-DGCR5表达状态患者临床资料比较[例(%)]

Table 1. Comparison of clinical data of patients with different LncRNA-DGCR5 expression states[cases (%)]

项目	例数	低表达组(n=41)	高表达组(n=64)	χ²值	P值
性别
男性	62	23(56.10)	39(60.94)	0.242	0.623
女性	43	18(43.90)	25(39.06)
年龄
≤60岁	71	26(63.41)	45(70.31)	0.543	0.461
＞60岁	34	15(36.59)	19(29.69)
肿瘤部位
中央型	69	25(60.98)	44(68.75)	0.670	0.413
周围型	36	16(39.02)	20(31.25)
病理类型
鳞癌	58	25(60.98)	33(51.56)	0.896	0.344
腺癌	47	16(39.02)	31(48.44)
肿瘤分化程度
低分化	37	26(63.41)	11(17.19)	23.401	＜0.001
中高分化	68	15(36.59)	53(82.81)
肿瘤最大径
≤4 cm	59	22(53.66)	37(57.81)	0.175	0.676
＞4 cm	46	19(46.34)	27(42.19)
TNM分期
Ⅰ~Ⅱ期	61	18(43.90)	43(67.19)	5.566	0.018
Ⅲ~Ⅳ期	44	23(56.10)	21(32.81)
淋巴结转移
有	47	16(39.02)	31(48.44)	0.896	0.344
无	58	25(60.98)	33(51.56)

下载: 导出CSV

表 2 NSCLC患者中位DFS影响因素的单因素分析

Table 2. Univariate analysis of median DFS in NSCLC patients

项目	例数	中位DFS (月)	log-rank χ²值	P值
性别
男性	62	30.45	1.314	0.252
女性	43	28.97
年龄
≤60岁	71	29.54	0.914	0.522
＞60岁	34	31.37
肿瘤部位
中央型	69	29.33	0.249	0.801
周围型	36	31.14
病理类型
鳞癌	58	29.61	1.145	0.369
腺癌	47	30.86
分化程度
低分化	37	28.15	9.074	0.013
中高分化	68	NR
肿瘤最大径
≤4 cm	59	29.65	0.176	0.897
＞4 cm	46	30.19
TNM分期
Ⅰ~Ⅱ期	61	NR	5.105	0.028
Ⅲ~Ⅳ期	44	28.66
淋巴结转移
有	47	27.45	12.116	＜0.001
无	58	NR
注：NR表示未达到。

下载: 导出CSV

表 3 NSCLC患者中位DFS影响因素的Cox回归分析

Table 3. Cox regression analysis of factors influencing median DFS in NSCLC patients

变量	B	SE	Waldχ²	P值	HR值(95% CI)
分化程度	0.561	0.217	6.684	0.010	1.752(1.145~2.681)
TNM分期	0.671	0.188	12.739	＜0.001	1.956(1.353~2.828)
淋巴结转移	0.623	0.158	15.548	＜0.001	1.865(1.368~2.541)
LncRNA-DGCR5低表达	0.525	0.194	7.323	0.007	1.690(1.156~2.473)
注：将肿瘤分化程度(低分化=1，高分化=0)、TNM分期(Ⅲ~Ⅳ期=1，Ⅰ~Ⅱ期=0)、淋巴结转移(有转移=1，无转移=0)及LncRNA-DGCR5表达(连续型变量，以实际值赋值)作为自变量，将是否死亡作为因变量(1=死亡，0=存活)。

下载: 导出CSV

参考文献(21)

[1]	许子宜, 郝学志, 汪麟, 等. EGFR-TKI联合安罗替尼用于晚期EGFR突变非小细胞肺癌患者TKI缓慢进展后的疗效与安全性[J]. 癌症, 2024, 43(1): 27-35. XU Z Y, HAO X Z, WANG L, et al. Efficacy and safety of EGFR-TKI combined with anrotinib in patients with advanced EGFR-mutated non-small cell lung cancer after slow progression of TKI[J]. Cancer, 2024, 43(1): 27-35.
[2]	刘力华, 闫茂慧, 李宏奇, 等. 螺旋断层放射治疗联合重组人血管内皮抑制素治疗不可切除且不能耐受同步放化疗的Ⅲ期非小细胞肺癌[J]. 武警医学, 2023, 34(9): 752-756, 762. LIU L H, YAN M H, LI H Q, et al. Spiral tomotherapy combined with recombinant human endostatin in the treatment of stage Ⅲ non-small cell lung cancer that is unresectable and cannot tolerate concurrent chemoradiotherapy[J]. Chi J Arm Pol Med, 2023, 34(9): 752-756, 762.
[3]	余璐, 李俊毅, 高苗苗, 等. 早期非小细胞肺癌患者立体定向放射治疗的预后分析[J]. 中国肺癌杂志, 2023, 26(4): 274-280. YU L, LI J Y, GAO M M, et al. Prognosis of patients with early non-small cell lung cancer treated with stereotactic radiotherapy[J]. Chi J Lun Can, 2023, 26(4): 274-280.
[4]	段玉青, 贾云泷, 王佳丽, 等. lncRNA DGCR5通过上调EGFR表达促进食管鳞状细胞癌TE1细胞的恶性生物学行为[J]. 中国肿瘤生物治疗杂志, 2020, 27(9): 1006-1011. DUAN Y Q, JIA Y L, WANG J L, et al. lncRNA DGCR5 promotes malignant biological behavior of TE1 cells in esophageal squamous cell carcinoma by up-regulating EGFR expression[J]. Chi J Can Bio, 2020, 27(9): 1006-1011.
[5]	王敏娜, 张颖, 吴琳, 等. LncRNA DGCR5在宫颈癌中的表达及其与临床特征及预后的关系[J]. 解剖科学进展, 2022, 28(2): 204-208. WANG M N, ZHANG Y, WU L, et al. Expression of LncRNA DGCR5 in cervical cancer and its relationship with clinical features and prognosis[J]. Adv Ana Sci, 2022, 28(2): 204-208.
[6]	中国初级卫生保健基金会肿瘤精准诊疗专业委员会, 中国抗癌协会肿瘤精准治疗专业委员会, 中国抗癌协会肿瘤病理专委会肺癌学组, 等. 基于RNA-based NGS检测非小细胞肺癌融合基因临床实践中国专家共识[J]. 中国肺癌杂志, 2023, 26(11): 801-812. Foundation, Cancer Precision Therapy Committee of China Anti-cancer Association, Lung Cancer Group of Tumor Pathology Committee of China Anti-cancer Association, et al. Clinical Practice of RNA-based NGS Detection of fusion gene in non-small cell Lung Cancer[J]. Chi J Lun Can, 2023, 26(11): 801-812.
[7]	张波, 方文涛, 钟华. 肺癌第9版TNM分期解读[J]. 中华肿瘤杂志, 2024, 46(3): 206-210. ZHANG B, FANG W T, ZHONG H. Interpretation of TNM staging in the 9th edition of lung cancer[J]. Chi J Can, 2024, 46(3): 206-210.
[8]	YANG Y, SHANG H. Silencing lncRNA-DGCR5 increased trophoblast cell migration, invasion and tube formation, and inhibited cell apoptosis via targeting miR-454-3p/GADD45A axis[J]. Mol Cell Biochem, 2021, 476(9): 3407-3421.
[9]	卢红, 陈伟, 王健, 等. mRECIST与iRECIST标准评价肝细胞癌免疫治疗疗效的对比研究[J]. 中国普通外科杂志, 2023, 32(7): 1023-1031. LU H, CHEN W, WANG J, et al. Comparative study of mRECIST and iRECIST criteria in evaluating the efficacy of immunotherapy for hepatocellular carcinoma[J]. Chi J Gen Sur, 2023, 32(7): 1023-1031.
[10]	张振华, 付伟, 刘伟良, 等. PET/CT影像组学结合LncRNA-DGCR5在NSCLC精准医疗中的应用研究[J]. 天津医药, 2023, 51(9): 1011-1015. ZHANG ZH H, FU W, LIU W L, et al. Application of PET/CT imaging combined with LncRNA-DGCR5 in precision medicine of NSCLC[J]. Tianjin Med, 2023, 51(9): 1011-1015.
[11]	段玉青, 王梦杰, 王洪琰, 等. lncRNA DGCR5在食管鳞状细胞癌组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2020, 27(4): 416-419. DUAN Y Q, WANG M J, WANG H Y, et al. Expression of lncRNA DGCR5 in esophageal squamous cell carcinoma and its clinical significance[J]. Chi J Can Bio, 2020, 27(4): 416-419.
[12]	李硕, 李青珊, 范志刚. LncRNA DGCR5在恶性肿瘤中的研究进展[J]. 肿瘤预防与治疗, 2023, 36(10): 892-899. LI S, LI Q S, FAN Z G. Research progress of LncRNA DGCR5 in malignant tumors[J]. Can Pre Tre, 2023, 36(10): 892-899.
[13]	籍玉青, 尹永波, 邱金霞. lncRNA DGCR5通过靶向调控miR-21抑制鼻咽癌细胞的增殖、侵袭和迁移[J]. 中国老年学杂志, 2022, 42(11): 2791-2795. JI Y Q, YIN Y B, QIU J X. lncRNA DGCR5 inhibits the proliferation, invasion and migration of nasopharyngeal carcinoma cells through targeted regulation of miR-21[J]. Chinese Journal of Gerontology, 2022, 42(11): 2791-2795.
[14]	AL-HAWARY S I S, RODRIGUES P, BANGALI H, et al. The role of long noncoding RNA DGCR5 in cancers: focus on molecular targets[J]. Cell Biochem Funct, 2024, 42(2): e3949. DOI: 10.1002/cbf.3949.
[15]	DUAN Y Q, JIA Y, WANG J, et al. Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1[J]. Cell Death Dis, 2021, 12(6): 587.
[16]	HE Z, LONG J, YANG C, et al. LncRNA DGCR5 plays a tumor-suppressive role in glioma via the miR-21/Smad7 and miR-23a/PTEN axes[J]. Aging (Albany NY), 2020, 12(20): 20285-20307.
[17]	陈艺, 张腾龙, 杨哲, 等. IL-33、肿瘤微血管密度及淋巴管密度在非小细胞肺癌中的表达及对预后的影响[J]. 新医学, 2020, 51(5): 370-377. CHEN Y, ZHANG T L, YANG Z, et al. Expression of IL-33, tumor microvessel density and lymphatic vessel density in non-small cell lung cancer and its effect on prognosis[J]. New Med, 2020, 51(5): 370-377.
[18]	赵论, 张浩然, 石默晗, 等. 安罗替尼联合多西他赛二线治疗无驱动基因晚期非小细胞肺癌的临床疗效观察[J]. 中华全科医学, 2020, 18(4): 537-541. doi: 10.16766/j.cnki.issn.1674-4152.001292 ZHAO L, ZHANG H R, SHI M H, et al. Clinical efficacy of antirotinib combined with docetaxel in the treatment of advanced non-small cell lung cancer without driver gene[J]. Chinese Journal of General Practice, 2020, 18(4): 537-541. doi: 10.16766/j.cnki.issn.1674-4152.001292
[19]	SUN Y, SUN H. Propofol exerts anticancer activity on hepatocellular carcinoma cells by raising lncRNA DGCR5[J]. J Cell Physiol, 2020, 235(3): 2963-2972.
[20]	邱卫华, 郭晴晴, 罗建喜. 瑞芬太尼通过上调lncRNA DGCR5表达影响卵巢癌细胞增殖和转移的机制研究[J]. 实用临床医药杂志, 2023, 27(16): 43-49, 62. QIU W H, GUO Q Q, LUO J X. Effects of remifentanil on proliferation and metastasis of ovarian cancer cells through up-regulation of lncRNA DGCR5 expression[J]. J Pra Cli Med, 2023, 27(16): 43-49, 62.
[21]	白云波, 张振华, 范志刚. lncRNA DGCR5在非小细胞肺癌组织中的表达及其与临床病理特征的相关性分析[J]. 现代生物医学进展, 2023, 23(2): 396-400. BAI Y B, ZHANG Z H, FAN Z G. Expression of lncRNA DGCR5 in non-small cell lung cancer and its correlation with clinicopathological features[J]. Progress in Modern Biomedicine, 2023, 23(2): 396-400.